Merck built a wall of patents to keep a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...

The Cancer Calculus, coordinated by the International Consortium of Investigative Journalists with Deutsche Welle and 46 ...

Keytruda, manufactured by the US-based Merck & Co, is an immunotherapy drug that has become one of the world’s best-selling ...

Merck (NYSE:MRK) received expanded EU approval for KEYTRUDA-based regimens in platinum-resistant ovarian cancer, making it ...

Some of the philanthropic foundations that fund ICIJ have programs or campaigns advocating for reform of the pharmaceutical ...

First approved by the US FDA in 2014 for advanced skin cancer, Keytruda is now used globally for certain lung cancers, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in ...

Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company’s ...

Once a company product is delivered through the legitimate supply chain to a distributor, the company does not have ...

Explore the U.S. patents Merck deploys to stymie competition and keep revenues for its blockbuster cancer drug flowing as ...

Keytruda, developed by Merck & Co., belongs to a class of drugs known as immune checkpoint inhibitors, which help the immune ...

Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it ...